Jefferies downgrades UCB, warns of 15% Bimzelx sales hit by 2026
NegativeFinancial Markets

Jefferies has downgraded UCB, indicating that the company's Bimzelx sales could face a significant decline of 15% by 2026. This news is concerning for investors and stakeholders as it suggests potential challenges for UCB in maintaining its market position and revenue streams. Understanding these projections is crucial for those following the pharmaceutical industry, as it highlights the volatility and risks associated with drug sales.
— Curated by the World Pulse Now AI Editorial System












